## **Resource Summary Report**

Generated by <u>dkNET</u> on May 18, 2025

# **SynergyFinder**

RRID:SCR\_019318 Type: Tool

**Proper Citation** 

SynergyFinder (RRID:SCR\_019318)

### **Resource Information**

URL: https://bioconductor.org/packages/synergyfinder/

Proper Citation: SynergyFinder (RRID:SCR\_019318)

**Description:** Software R package as efficient implementations for all popular synergy scoring models for drug combinations, including HSA, Loewe, Bliss and ZIP and visualization of synergy scores as either two dimensional or three dimensional interaction surface over dose matrix. Used to calculate and visualize synergy scores for drug combinations.

Synonyms: synergyfinder

**Resource Type:** software application, software toolkit, data visualization software, data processing software, software resource

Defining Citation: DOI:10.1007/978-1-4939-7493-1\_17

**Keywords:** Synergy scores, drug combinations, popular synergy scoring models, dimensional interaction surface, dose matrix, bio.tools

#### Funding:

Availability: Free, Available for download, Freely available

Resource Name: SynergyFinder

Resource ID: SCR\_019318

Alternate IDs: biotools:synergyfinder

Alternate URLs: https://bio.tools/synergyfinder

Record Creation Time: 20220129T080344+0000

Record Last Update: 20250517T060420+0000

## **Ratings and Alerts**

No rating or validation information has been found for SynergyFinder.

No alerts have been found for SynergyFinder.

## Data and Source Information

Source: <u>SciCrunch Registry</u>

## **Usage and Citation Metrics**

We found 352 mentions in open access literature.

Listed below are recent publications. The full list is available at <u>dkNET</u>.

Huang C, et al. (2025) Targeting p38? synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma. Cell biology and toxicology, 41(1), 35.

Zhao D, et al. (2025) Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening. Neoplasia (New York, N.Y.), 60, 101100.

Zhang J, et al. (2025) The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib. Current research in pharmacology and drug discovery, 8, 100212.

Watanabe A, et al. (2025) Noncanonical TCA cycle fosters canonical TCA cycle and mitochondrial integrity in acute myeloid leukemia. Cancer science, 116(1), 152.

Sun L, et al. (2025) Selective inhibition of TGF-?-induced epithelial-mesenchymal transition overcomes chemotherapy resistance in high-risk lung squamous cell carcinoma. Communications biology, 8(1), 152.

Verbeke S, et al. (2025) Dual inhibition of BET and EP300 has antitumor activity in undifferentiated pleomorphic sarcomas and synergizes with ferroptosis induction. Translational oncology, 52, 102236.

Zhang Y, et al. (2025) Super-silencer perturbation by EZH2 and REST inhibition leads to large loss of chromatin interactions and reduction in cancer growth. Nature structural & molecular biology, 32(1), 137.

Kawai-Kawachi A, et al. (2025) Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors. Cancer research, 85(1), 154.

Zheng K, et al. (2025) Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma. Cancer chemotherapy and pharmacology, 95(1), 21.

Chan SPY, et al. (2025) Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer. Experimental hematology & oncology, 14(1), 5.

Pacaud R, et al. (2025) Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors. Breast cancer research : BCR, 27(1), 8.

Verhees F, et al. (2025) Exploring the antiproliferative effect of PI3K/Akt/mTOR pathway and CDK4/6 inhibitors in human papillomavirus?positive and ?negative head and neck squamous cell carcinoma cell lines. International journal of oncology, 66(2).

Ravlo E, et al. (2025) Synergistic combination of orally available safe-in-man pleconaril, AG7404, and mindeudesivir inhibits enterovirus infections in human cell and organoid cultures. Cellular and molecular life sciences : CMLS, 82(1), 57.

Vighetto V, et al. (2024) Anti-CD38 targeted nanotrojan horses stimulated by acoustic waves as therapeutic nanotools selectively against Burkitt's lymphoma cells. Discover nano, 19(1), 28.

Zhu Y, et al. (2024) CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI insight, 9(2).

Chen A, et al. (2024) PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Molecular cancer therapeutics, 23(10), 1494.

Burov A, et al. (2024) Multikinase inhibitors modulate non-constitutive proteasome expression in colorectal cancer cells. Frontiers in molecular biosciences, 11, 1351641.

Futran AS, et al. (2024) Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity. iScience, 27(5), 109693.

Hasan Bou Issa L, et al. (2024) MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma. iScience, 27(4), 109417.

Bwanika HC, et al. (2024) Targeting autophagy as a therapeutic strategy in pediatric acute lymphoblastic leukemia. Scientific reports, 14(1), 4000.